Cover Image
市場調查報告書

Alitair Pharmaceuticals, Inc.的產品平台分析

Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321363
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Alitair Pharmaceuticals, Inc.的產品平台分析 Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月30日 內容資訊: 英文 27 Pages
簡介

Alitair Pharmaceuticals, Inc.ha,是開發呼吸系統疾病相關治療藥的生物醫藥品企業。還有進行著止咳藥相關的處方藥及成藥的開發。

本報告提供Alitair Pharmaceuticals, Inc.的治療藥開發平台的各現狀及各開發階段比較分析,標的,各給藥途徑,各分子類型,各作用機制的治療藥的評估,最近開發平台趨勢相關資訊等。

Alitair Pharmaceuticals, Inc.的基本資料

Alitair Pharmaceuticals, Inc.概要

  • 主要資訊
  • 企業資料

Alitair Pharmaceuticals, Inc.:R&D概要

  • 主要的治療範圍

Alitair Pharmaceuticals, Inc.:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Alitair Pharmaceuticals, Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 在前臨床階段的產品/聯合治療模式

Alitair Pharmaceuticals, Inc.:開發階段不明的開發中產品

  • 開發階段不明的產品/聯合治療模式

Alitair Pharmaceuticals, Inc.:藥物簡介

  • erdosteine
  • ALT-07
  • ALT-09
  • benzonatate polacrilex

Alitair Pharmaceuticals, Inc.:開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Alitair Pharmaceuticals, Inc.:最近的開發平台趨勢

Alitair Pharmaceuticals, Inc.:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07831CDB

Summary

Global Markets Direct's, 'Alitair Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Alitair Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Alitair Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Alitair Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Alitair Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Alitair Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

  • Evaluate Alitair Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Alitair Pharmaceuticals, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Alitair Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Alitair Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Alitair Pharmaceuticals, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Alitair Pharmaceuticals, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alitair Pharmaceuticals, Inc. Snapshot
    • Alitair Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Alitair Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Alitair Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Alitair Pharmaceuticals, Inc. - Pipeline Products Glance
    • Alitair Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alitair Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
    • Alitair Pharmaceuticals, Inc. - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • Alitair Pharmaceuticals, Inc. - Drug Profiles
    • erdosteine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALT-09
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • doxofylline
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • benzonatate polacrilex
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Alitair Pharmaceuticals, Inc. - Pipeline Analysis
    • Alitair Pharmaceuticals, Inc. - Pipeline Products by Target
    • Alitair Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Alitair Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Alitair Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Alitair Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Alitair Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alitair Pharmaceuticals, Inc., Key Information
  • Alitair Pharmaceuticals, Inc., Key Facts
  • Alitair Pharmaceuticals, Inc. - Pipeline by Indication, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alitair Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alitair Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Alitair Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Alitair Pharmaceuticals, Inc. - Phase II, 2015
  • Alitair Pharmaceuticals, Inc. - Preclinical, 2015
  • Alitair Pharmaceuticals, Inc. - Unknown, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Target, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Alitair Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Alitair Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015
  • Alitair Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015
  • Alitair Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Alitair Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top